Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

J&J's Tremfya Shows Sustained Remission In Crohn's Disease Through 3 Years

(RTTNews) - Johnson & Johnson (JNJ) reported three-year data showing sustained clinical and endoscopic remission with Tremfya (guselkumab) in adults with moderately to severely active Crohn's disease.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

More from Tuesday 13 October →